Commentary

Dietary supplement intake during pregnancy; better safe than sorry?

Alie de Boer*, Aalt Bast, Roger Godschalk

* Food Claims Centre Venlo, Maastricht University Campus Venlo, Faculty of Humanities and Sciences, Venlo, The Netherlands
b Department of Pharmacology and Toxicology, Faculty of Health Medicine and Life Sciences, Maastricht University, Maastricht, The Netherlands

A R T I C L E   I N F O

Keywords:
Fetal programming
Nutrigevalence
Dietary supplements
Novel food
European food law
Food safety

A B S T R A C T

Consumption of dietary supplements and specifically niche products such as supplements targeting pregnant women is increasing. The advantages of dietary supplementation during pregnancy with folic acid have been established, but health effects of many other supplements have not been confirmed. EU and US legislation on dietary supplements requires the product to be safe for the direct consumer, the mother. Long-term health effects for the fetus due to fetal programming (in utero adaptation of the fetal epigenome due to environmental stimuli such as supplementation) are not taken into account. Such epigenetic alterations can, however, influence the response to health challenges in adulthood. We therefore call for both conducting research in birth cohorts and animal studies to identify potential health effects in progeny of supplement consuming mothers as well as the establishment of a nutrigevalence scheme to identify favorable and adverse effects post-marketing. The acquired knowledge can be used to create more effective legislation on dietary supplement intake during pregnancy for safety of the child. Increasing knowledge on the effects of consuming supplements will create a safer environment for future mothers and their offspring to optimize their health before, during and after pregnancy.

1. Introduction

The popularity of dietary supplements, in this paper defined as sources of concentrated micro- or macronutrients, is rising together with an increasing interest of consumers in potential health enhancing foods (Euromonitor International, 2015; Menrad, 2003; Teichner and Lesko, 2013). Especially niche products, such as dietary supplements that target women of reproductive age and pregnant women, increased their market share over the past decade. For example, from 2010 to 2015, the multivitamin market yearly grew 2 to 19 percent in the eight countries with the highest sales of multivitamins (UK, Brazil, USA, Russia, Mexico, Italy, South Korea and China). In the UK alone, the sales of multivitamins targeting pregnant women grew approximately two percent in these five years, ending up representing 17% of the total multivitamin market in the UK (Schmidt, 2015). Although the availability of epidemiological data is limited, cross-sectional and cohort studies suggest an increase in daily use of supplements (Kim et al., 2014; Radimer et al., 2004; Sullivan et al., 2009). Different studies report that females use different dietary supplements more often than men and especially those persons with increased interest in health were more regularly consumers of dietary supplements (Bailey et al., 2011; Dickinson et al., 2014; Radimer et al., 2004; Rock, 2007). Additionally, in specific subgroups including athletes and long-term cancer survivors at reproductive age, the use of dietary supplements has increased (Knappik et al., 2016; Velicer and Ulrich, 2008; Wardenaar et al., 2016).

The beneficial effect of dietary supplementation before and during pregnancy has only been established for folic acid: folic acid is important for growth and development of both the fetus and maternal tissues and a sufficient intake of folic acid can be guaranteed by supplementing the diet (De-Regil et al., 2015; EFSA NDA Panel, 2009; Eichholzer et al., 2006; Kaiser and Allen, 2008). In various countries, foods are (required to be) fortified with folic acid, whilst the European strategy is to advise the target group (women with the intention to become pregnant and pregnant women) to supplement their diet (Czeizel et al., 2013). Whereas fortification can reach a broader public, it is suggested to expose the general public to too high amounts of folic acid while a large part of the target group may still not meet their recommended daily intake (Czeizel et al., 2013; Osterhues et al., 2013).

Women of childbearing age and pregnant women have been reported to increasingly use dietary supplements with other ingredients such as the omega-3 polyunsaturated fatty acid docosahexaenoic acid (DHA), calcium, vitamin D, zinc and multivitamins, but also with herbal ingredients such as Echinacea and ginger (Buppasiri et al., 2015; Cave et al., 2016; De-Regil et al., 2016; Imhoff-Kunsch et al., 2012; Ota et al., 2014; Kunsch et al., 2012; Ota et al., 2016). The use of such ingredients is not explicitly regulated in the EU and US whereas for others such as folic acid, specific requirements have been established (Aalt Bast et al., 2013). Furthermore, the use of such ingredients is not explicitly regulated in the EU and US whereas for others such as folic acid, specific requirements have been established (Aalt Bast et al., 2013).
used to supplement the diet’ (Dietary Supplement Health and Education Act of 1994, n.d.). Although food products should be safe when they are available for sale, no specific safety dossier is required before dietary supplements are placed on the market. The DSHEA gives the Food and Drug Administration (FDA) in the USA the authority to safeguard the public from unsafe products (Dietary Supplement Health and Education Act of 1994, n.d.; U.S. Food and Drug Administration, 2014). Therefore, adequate information must be provided to the FDA before a new dietary ingredient can be brought to market and when the FDA shows that the dietary ingredient poses a ‘significant or unreasonable risk’ to consumer safety, the product can be removed from the market (Dietary Supplement Health and Education Act of 1994, n.d.). Currently, however, the long-term effects of dietary supplements consumed during pregnancy or during breastfeeding are insufficiently known to make a proper decision about potential risks and consumer safety. In Europe, only new ingredients or products produced by new techniques are subject to the safety review of the European Food Safety Authority (EFSA), a crucial aspect in the pre-market authorization by the European Commission for such a novel food under the Novel Food Regulation (Regulation (EU) 2015/2283) (European Parliament and Council of the European Union, 2015; Turck et al., 2016). The European Commission has described in their recommendation that the wholesomeness of food products, influenced by i.a. the nutritional, toxicological and metabolic properties of a product, is key in assessing the authorization of a novel food (European Commission, 1997; Turck et al., 2016). Next to considering the nutritional implications of a novel food, this recommendation also suggests to take short and long term effects of consuming a novel food into account and to pay specific attention therein to groups with specific nutritional requirements, such as pregnant and lactating women (European Commission, 1997). The health effects of offspring in later life do however not seem to be taken into consideration when safety is tested. As the effects of the maternal dietary status and maternal consumption during pregnancy on the development of the fetus become more apparent, the question arises how these findings can be incorporated in legislation, and specifically in dietary supplement regulation.

3. Fetal programming

Before birth, the fetus is affected by various environmental factors such as maternal dietary status, food intake or the intake of dietary supplements by the mother (Fig. 1). The fetus is thought to adapt to these in utero circumstances by making changes to the epigenome that are potentially necessary for survival, which can persist in later life (Gicquel et al., 2008; Godfrey and Barker, 2001; Vanhees et al., 2014). In short, the epigenome includes various chemical changes to the structure of DNA without changing the underlying DNA sequence. These chemical changes can be either on the DNA bases (e.g., methylation of cytosine in CpG sequences) or on proteins that are involved in folding the DNA (e.g., histone modifications). These epigenetic modifications are involved in regulating gene expression and therefore affect growth and tissue differentiation, especially in the developing child. Moreover, these modifications can be passed down to the offspring via transgenerational epigenetic inheritance. The DNA sequence in the genome is largely static within an individual, but the epigenome is dynamic and can be altered by environmental conditions, especially by dietary habits (Vanhees et al., 2014). These adaptations to the environmental circumstances by the fetal epigenome may result in altered structures and functioning of the organism, which is also known under different terms, including ‘phenotype induction’, ‘fetal programming’ (Burdge et al., 2007; Gicquel et al., 2008; Godfrey et al., 2013; Godfrey and Barker, 2001; Vanhees et al., 2014) or the ‘Developmental origins of (adult) health and disease’ (DOHAD) hypothesis (47–50). Since different organ systems develop on various critical time points, environmental stimuli or triggers can influence the development of the fetus differently (Al-Ghazali et al., 1989; Barker, 2012; Chmurzyńska, 2010;
Godfrey and Barker, 2001).

As depicted in Fig. 1, stable alterations to the fetal epigenome prevail later in life and can influence the response to environmental stimuli in adulthood (Brenseke et al., 2013; Gicquel et al., 2008; Godfrey et al., 2007). When later in life environmental conditions interact with the altered epigenome, this mismatch of environmental stimuli with the altered epigenome can increase the risk of developing diseases. An example of such a mismatch was shown in children that were in utero during the Dutch Famine (hunger winter of 1944–1945). These children have an increased risk for obesity, not because of the protein and caloric deficiency only, but because they additionally encountered a Western type of diet later in life leading to a mismatch between the in utero environment and the environment in adulthood (Gluckman, 2004; Grandjean, 2008; Roseboom et al., 2001). Animal models of obesity (mothers consuming hyper-caloric diets) also demonstrated negative effects in offspring such as increased systolic blood pressure and higher fasting plasma insulin (Brenseke et al., 2013; Roseboom et al., 2011; Vickers et al., 2000), indicating that not only under-nutrition, but also over-nutrition can have ‘programming’ consequences.

4. Dietary supplementation and fetal programming

Various reviews have shown that the maternal dietary intake influences the health status of offspring (Burdge et al., 2007; Chmurzynska, 2010; Lillycrop, 2011). Micronutrients are well known modulators of the epigenome (for instance the effect of vitamin D on the epigenome (Fetahu et al., 2014) and various roles of nutrients in epigenetic processes reviewed in (Choi and Friso, 2010)). These reviews however mainly focus on the potential negative effects of deficiencies of the maternal diet or negative consequences following the intake of a sub-optimal maternal diet, whereas the current trend towards optimizing health is also focusing on women of childbearing age not necessarily having deficiencies (Schmidt, 2015). Supplement use by pregnant women is therefore expected to rise. The following four short cases illustrate why also intake of dietary supplements with concentrated nutrients in a healthy maternal dietary status and the offspring’s health, should somehow be taken into account in future safety regulations. Evidence for the programming effect of folic acid is mainly coming from studies in humans, whereas the long term effects of certain flavonoids (e.g., quercetin and genistein) on offspring’s health originates predominantly from animal studies.

4.1. Folic acid

Since 1992, dietary supplementation with folic acid is recommended to decrease the risk on neural tube defects (Eichholzer et al., 2006; Gezondheidsraad, 2008). Although this effect of folic acid has been established by epidemiological studies, the exact effect of folic acid on the multistep process of developing the human neural tube is however still not completely understood (Osterhues et al., 2013). Folic acid can for instance act as a co-enzyme and affects the construction and repair of DNA (Czeizel et al., 2013). The supplementation of 0.4 mg/day folic acid during the first trimester of pregnancy is considered as safe for both the women and their unborn children and it should be noted that the widely recommended use of folic acid before and during pregnancy is undisputed to minimize the risk for neural tube defects as well as other congenital malformations (De-Regil et al., 2015; Eichholzer et al., 2006). Supplements consumed by the mother before or during the fetal development could however affect the fetal epigenome (Pauwels et al., 2017). Various cohort studies and reviews suggest that maternal supplementation with folic acid in late pregnancy can lead to an increased risk for developing asthma or other (allergic) diseases in childhood. However, these data are postulated by studies of varying quality and results are inconclusive (Greenop et al., 2014; Häberg et al., 2009; Magdelijns et al., 2011; Martinussen et al., 2012; Schüz et al., 2007; Wang et al., 2015; Whitrow et al., 2009). Still, epidemiological studies performed so far, do not consider the presence of potential triggers or challenges, for instance exposure to allergens, and whether children of mothers who took folic acid supplements react
differently to these allergens. Additionally, a recent study by Pauwels et al. (2017) suggests that maternal dietary or supplemental intake of methyl-group donors (including folate) can influence the infant’s DNA methylation patterns in genes related to metabolism, growth, appetite regulation, and maintenance of DNA methylation reactions. Thus, although maternal folic acid supplementation during pregnancy is undisputed, a follow up at later stages in the child’s life is warranted to further optimize the dose of folic acid or to optimally select the time-window during pregnancy at which additional intake of folic acid should be recommended.

4.2. Quercetin

Dietary intake of supplements containing flavonoids and antioxidants in general is popular amongst pregnant women (Barens et al., 2016). Consequences of dietary supplementation with the flavonoid quercetin on the offspring’s health have been established in several animal studies (Vanhees et al., 2013, 2012; 2011b). Quercetin is a dietary antioxidant, found mainly in onions, apples and tea, which is claimed to have various beneficial health effects as antioxidant and anti-inflammatory properties (Aherne and O’Brien, 2002; Boots et al., 2008; Vanhees et al., 2012). The average daily dietary intake of quercetin in humans with a Western type of diet is 4–68 mg per day (Skibola and Smith, 2000), but a much higher intake can be reached because the daily dose of quercetin supplements lies between 200 and 1800 mg quercetin (manufacturers’ recommendations) (Egert et al., 2008; Mennen et al., 2005). These high dose supplements are freely available in pharmacies and drugstores. Therefore, daily quercetin supplementation, which results in increased plasma quercetin levels (Egert et al., 2008), can lead to increased exposures of the fetus to high concentrations of quercetin and its metabolites. Feeding very high doses of quercetin (333 mg/kg feed) to pregnant mice did not appear to be teratogenic to their fetuses (Frater et al., 2008), but long term health effects have been described: in mice, the maternal consumption of quercetin is shown to upregulate the gene expression of enzymatic antioxidants in offspring and the response of hepatic cells to oxidative stress seems to be altered (Vanhees et al., 2013, 2012). This could theoretically improve the health status of the offspring by decreasing oxidative stress markers, as well as potentially protecting against induced DNA adduct formation (Vanhees et al., 2012, 2011b). On the other hand, relatively high prenatal concentrations of quercetin were also shown to lead to increased iron storage in the liver, which could put the offspring at risk for a toxic iron overload (Vanhees et al., 2011b).

4.3. Phyto-estrogens

Adults consuming modest amounts of soy-containing foods have a total daily isoflavone intake of 1–9 mg. However, people who consume large amounts of soy products, like vegetarians, have a higher intake of isoflavones such as genistein and daidzein. In Asian countries the daily intake of isoflavones can reach 20–40 mg, because of the high consumption of soy (Skibola and Smith, 2000). Intake of genistin supplements is becoming increasingly popular, especially for women, because it is suggested to result in decreased breast cancer risk (Coward et al., 1993). The manufacturers of supplements recommend a dose of up to 6 tablets of 25–100 mg per day. Additionally, it should be noted that the metabolism of these isoflavones is different in the fetus, and as a result, fetal cord blood contains higher concentrations of for instance genistein than maternal blood (Coward et al., 1993). Intake by young children can also be high, when they are being fed with soy-based formulas (also see the American Academy of Pediatrics statement on Use of Soy Protein-Based Formulas in Infant Feeding from 2008 (Bhatia and Greer, 2008)). However, there is concern about the intake of isoflavones like genistein during pregnancy, because it mimics the human hormone estrogen (therefore it is called a phyto-estrogen). Animal studies indeed indicate that intake of genistein during pregnancy changes the epigenetic landscape of offspring (Dolino et al., 2006) with subsequent changes in gene expression (Vanhees et al., 2011a). Moreover, maternal intake of genistein has been related to early onset of puberty in female offspring and alters the development of breast tissue, potentially leading to increased breast cancer risk in offspring at older ages (Hilakivi-Clarke et al., 2002; n.d.; Warri et al., 2008).

4.4. Multi micronutrient supplementation

Recently, a Cochrane systematic review on the safety of multi micronutrient supplement intake during pregnancy was published (Haider and Bhutta, 2015). Most of the studies that were included in the analyses were carried out in low and middle-income countries, where micronutrient deficiency is common among women of reproductive age. It was concluded that supplementation of pregnant women is beneficial with regard to preventing low birth weight and small for gestational age (SGA) pregnancies, whereas in studies that involved pregnant women of Western countries no such beneficial effects were found. Although the authors correctly conclude that interventions with micronutrients during pregnancy should focus on developing countries, it may also lead to additional intake of micronutrients by pregnant women in Western countries, because high intake of micronutrients is generally considered to be safe; better safe than sorry. However, in that same Cochrane review, safety was only assessed on basis of perinatal health only (e.g., preeclampsia, preterm births, maternal anemia, maternal and neonatal mortality, congenital abnormalities etc.), whereas long time health could not be studied. Taking into account the phenomenon of developmental programming, claiming safety of relatively high doses of micronutrients by supplementation may be premature. How should regulators thus deal with this uncertainty?

5. Epigenetic modulation in safety regulation

Long term effects of dietary supplements are thought to be mediated via epigenetic mechanisms. The role of epigenetics in reproductive toxicity is discussed in a recent report on the 2015 ECETOC workshop ‘The Role of Epigenetics in Reproductive Toxicity’, and the use of epigenetic findings in legislation was one major point of discussion (European Centre for Ecotoxicology and Toxicology of Chemicals, 2015). However, current knowledge is too limited and therefore legislative acts have not incorporated this aspect of safety yet.

Since the consumption of dietary supplements does not immediately give rise to adverse effects, it would not be realistic to ban these products form the market until such effects are fully identified. It would therefore be helpful to keep track of these potential negative effects via a nutrivismigilance scheme: a system in which adverse events that are attributed to food supplement intake or any other product related to food can be reported (ANSES - French Agency for Food Environmental and Occupational Health and Safety, 2014; Rihouey-Robini, 2014). In response to the thalidomide-affair in the 1960s, where birth defects in children were caused by thalidomide intake during pregnancy, so-called pharmacovigilance systems were developed to report adverse drug reactions after the drug was placed on the market (de Boer et al., 2015). A nutrivismigilance scheme, where reports concerning adverse responses following food supplement or functional food consumption can be filed by health professionals, producers and distributors, has so far only been established in France (ANSES - French Agency for Food Environmental and Occupational Health and Safety, 2014; Rihouey-Robini, 2014). By establishing a specific system to report adverse events and incidents with various food products as food supplements and novel foods, potential risks can be identified and thereby the scheme can contribute to consumer safety (Fig. 1).
6. Future perspectives

The consumption of supplements by women of childbearing age and pregnant women is expected to rise (Schmidt, 2015). The limited epidemiological data available indicate that many pregnant women consume dietary supplements and this number is thought to increase (Radimer et al., 2004; Sullivan et al., 2009). Although supplementing the diet with folic acid has proven health benefits, many other supplements used during pregnancy are currently not proven to be beneficial, unless they are used to compensate for deficiencies. With the maternal diet affecting the fetal genome through developmental programming, the consequences of supplementing should not be underestimated. We do not suggest that consuming dietary supplements endanger the health of the fetus, yet recognize the current lack of knowledge on the long-term health effects of the maternal diet, and more specifically supplements, on offspring. Next to a nutrigenomics scheme, currently ongoing birth-cohorts and animal studies could help to identify potential adverse and favorable health effects in progeny of supplement consuming mothers.

Birth-cohorts could be very helpful in discovering and possibly quantifying relationships between dietary intake of the mother and potential adverse or beneficial health effects in progeny. Other additional information on fetal programming could originate from animal studies, in which it is possible to consider the effects of specific environmental stimuli on the adapted and matured genome. In the study design, the consumption of dietary supplements by pregnant animals could be followed by exposure of the mature offspring to environmental stimuli including smoking, exposure to chemicals or use of pharmaceutical products. Although such studies could be helpful in identifying long term effects of prenatal exposure to dietary supplements, results obtained by animal studies can never fully clarify the effects found in humans. Therefore, the ultimate effects can only be evaluated by combining results obtained in animal and human studies with post-marketing events found via a nutrigenomics monitoring scheme.

Although foods are generally considered to be safe, in most cases the safety of these products in pregnancy is not required to be tested and therefore not established (Friedman, 2000; Schweitzer, 2006). This current lack of knowledge on safety and the need for scientific evidence regarding the health effects on offspring give rise to our call to develop a nutrigenomics scheme, by which adverse and favorable effects due to the consumption of specifically dietary supplements can be identified. Increasing knowledge on the effects of consuming supplements will create more effective legislation and thereby a safer environment for future mothers to optimize the health of their children before and during pregnancy.

Conflicts of interest

No conflicts of interest.

Transparency document

Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2018.03.014.

References


Conflicts of interest

No conflicts of interest.

Transparency document

Transparency document related to this article can be found online at http://dx.doi.org/10.1016/j.yrtph.2018.03.014.
Imho

Hilakivi-Clarke, L., Cho, E., Onojafe, I., Raygada, M., Clarke, R., n.d. Maternal exposure to

A. de Boer et al.

Hilakivi-Clarke, L., Cho, E., Cabanes, A., DeAssis, S., Olivo, S., Helferich, W., Lippman,

Hambidge, K.M., Krebs, N.F., Westcott, J.E., Garces, A., Goudar, S.S., Kodkany, B.S.,

Greenop, K.R., Miller, M., de Klerk, N.H., Scott, R.J., Attia, J., Ashton, L.J., Dalla-Pozza,

Radimer, K., Bindewald, B., Hughes, J., Ervin, B., Swanson, C., Picciano, M.F., 2009. Use of dietary supplements by pregnant and lac-


Ota, E., Mori, R., Middleton, P., Tobe-Gai, R., Mahomed, K., Miyazaki, C., Bhutta, Z.A.,

Martinussen, M.P., Risnes, K.R., Jacobsen, G.W., Bracken, M.B., 2012. Folic acid sup-


